Biotech News
Related news
CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
SNDXSyndax Pharmaceuticals2026-11-04 14:01 EST
Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026
EXELExelixis2026-11-03 21:05 EST
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
BMEABiomea Fusion2026-10-12 20:30 EST
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
URGNUroGen Pharma2026-11-03 13:00 EST
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
REGNRegeneron Pharmaceuticals2026-11-02 21:05 EST
Regeneron Announces Investor Conference Presentations
COGTCogent Biosciences2026-10-27 20:01 EST
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST
Coherus to Participate in Upcoming Investor Conferences
BNTXBioNTech2026-10-20 10:45 EST
BioNTech veröffentlicht am 3. November 2026 Ergebnisse für das dritte Quartal 2026 und informiert über operativen Fortschritt
ZNTLZentalis2026-10-18 22:05 EST
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
Nkarta
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...
Recent company news
NKTXNkarta2026-11-06 21:01 EST
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
NKTXNkarta2026-11-05 21:34 EST
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
NKTXNkarta2026-09-10 11:00 EST
Nkarta to Participate in September Investor Conferences
NKTXNkarta2026-09-08 11:00 EST
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
NKTXNkarta2026-08-10 20:24 EST
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Stock data
- Close
- 1.57 USD
- Market cap
- 208.2M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States